Cagrilintide vs tirzepatide (Mounjaro/Zepbound) Mechanism: Cagrilintide: Amylin agonist Tirzepatide: Dual GIP/GLP-1 agonist Both novel approaches Weight loss: Cagrilintide: 10-12% monotherapy Tirzepatide: 15-22% monotherapy Tirzepatide superior as single agent Administration: Both: Weekly subcutaneous injection Both: Similar convenience Side effects: Cagrilintide: Strong GI effects Tirzepatide: Moderate GI effects Similar overall profile Approval status: Cagrilintide: Investigational Tirzepatide: FDA approved Tirzepatide available now Cost (when both available): Likely similar ($1,000-1,500/month) Both premium weight loss options Verdict: Currently, tirzepatide better choice (approved, superior weight loss)
Sex differences in the efficacy of glucagon-like peptide1 receptor agonists for weight reduction: a systematic review and metaanalysis
Instead, people often describe: Feeling full sooner during meals Hunger returning more slowly Less intense cravings Easier decision-making around food This is because semaglutide slows digestion and influences hunger signaling in the brain, helping appetite feel more manageable rather than overwhelming
Why Trapped Gas Leads to Bloating Whether or not semaglutide causes excessive stomach distension, it can lead to more gas being produced because the guts motility is changed
Weeks 17 onwards: 2.4 mg once weekly if further weight loss is needed (maximum dose)
"The issue is not that they don't understand that they need to do that
